



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

31st January, 2017

Corporate Relationship Department
M/s. BSE Ltd
Dalal Street, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
"Exchange Plaza", Bandra–Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir,

Sub: Press Release

Please find enclosed herewith the Press Release for your information.


Thanking you.

Yours faithfully

For NATCO Pharma Limited

M Adinarayana

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)



Encl: a.a.



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref:PR/17/2016-17

Press Release

NATCO's partner Mylan Wins U.S. District Court Ruling Related to Copaxone® 40 mg/mL Patents

Hyderabad, India, January 31st, 2017

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced that the United States District Court for the District of Delaware issued a decision finding all asserted claims of four Orange Book-listed patents relating to Copaxone® 40 mg/mL invalid based on obviousness.

The invalidated patents are United States Patent Numbers 8,232,250; 8,399,413; 8,969,302; and 9,155,776, which are owned by Yeda Research & Development Co. Ltd. and licensed to Teva Pharmaceuticals Industries Ltd.

On Dec. 2, 2016, the U.S. Patent and Trademark Office's U.S. Patent Trial and Appeal Board (PTAB) reaffirmed a prior decision that three of these patents ('250, '413 and '302) are unpatentable in its inter partes review (IPR) proceedings initiated by NATCO's marketing partner Mylan. Mylan also challenged the '776 patent in an IPR proceeding. The PTAB is expected to issue its institution ruling on the '776 patent IPR by May 16, 2017.

Copaxone 40 mg/mL had U.S. sales of approximately \$3.3 billion for the 12 months ending Nov. 30, 2016, according to IMS Health.

Forwarded for favor of publication

For NATCO Pharma Limited

M. Adinarayana

M. Adinarayana

Company Secretary &

Vice President (Legal & Corp. Affairs)

